Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist officially approved by both the U.S. Food and Drug Administration (FDA) and the Turkish Medicines and Medical Devices Agency (TİTCK) for regulating blood glucose levels and reducing cardiovascular risks in the treatment of Type 2 diabetes. The Turkish Social Security Institution (SGK) reimburses the cost of this medication only for patients with documented diabetes who meet strict medical criteria, while no reimbursement is provided for off-label uses such as weight loss or obesity treatment. Although this biotechnological agent supports weight loss by suppressing appetite and is preferred in the management of metabolic disorders, it serves as a long-term medical support tool requiring ongoing use for excess weight and obesity treatment, unlike localized, incision-free procedures such as gastric Botox.
İçerik
What Is Trulicity?
Trulicity belongs to a specialized class of medications scientifically known as glucagon-like peptide-1 (GLP-1) receptor agonists. The human body naturally produces a GLP-1 hormone that is released from the intestines immediately after eating. This hormone stimulates the pancreas to regulate blood sugar levels while simultaneously sending satiety signals to the brain. However, the naturally produced hormone has a very short lifespan and is broken down by enzymes within only a few minutes after secretion. The Trulicity molecule has been specifically engineered in laboratory conditions to resist this rapid degradation. Thanks to this durable molecular structure, the medication remains active in the bloodstream for several days after being injected beneath the skin. Its prolonged duration of action allows patients to administer the medication only once per week instead of daily.
The medication works through a highly versatile mechanism that simultaneously affects several organs. Its primary target is the pancreas. Once it reaches the pancreas, it detects elevated blood glucose levels and increases insulin production accordingly. The greatest advantage of this mechanism is that insulin secretion increases only when blood sugar levels are elevated, significantly reducing the risk of sudden and dangerous hypoglycemia. At the same time, it suppresses the production of glucagon, another pancreatic hormone responsible for increasing blood glucose levels.
Its effects on the digestive system are equally significant. Trulicity slows gastric emptying. As food remains in the stomach longer, individuals experience prolonged feelings of fullness after meals. Simultaneously, the molecule reaches the central nervous system through the bloodstream and binds to appetite control centers in the brain, sending powerful signals indicating that the body has received sufficient nutrition and does not require additional energy. The combination of central appetite suppression and delayed gastric emptying enables patients to feel satisfied with much smaller meal portions throughout the day.
Which Conditions Is Trulicity Approved to Treat and Who Can Use It?
Trulicity first received approval from the U.S. Food and Drug Administration (FDA) in 2014 for improving blood glucose control in patients with Type 2 diabetes. As clinical research advanced, it became evident that the medication not only lowers blood glucose but also provides protection against many of diabetes’ harmful complications. After scientific studies demonstrated its positive effects on cardiovascular health, the FDA expanded its approved indications to include reducing the risk of major cardiovascular events in adults with Type 2 diabetes who either have established cardiovascular disease or are at high cardiovascular risk. As Type 2 diabetes became increasingly common among younger individuals, its approved use was later expanded to include pediatric patients aged 10 years and older.
According to the standards of the Turkish Medicines and Medical Devices Agency (TİTCK), the medication is licensed as a prefilled, single-use injection pen. It is available in different dosage strengths, and the appropriate dose is determined individually by the treating physician. Treatment typically begins with a lower dose, particularly in newly treated or older patients, allowing physicians to evaluate the patient’s tolerance. Depending on blood glucose response and medication tolerance, the dosage may be gradually increased. For patients already using oral diabetes medications, Trulicity may be added as combination therapy. The injection pen is designed for easy self-administration, typically into the abdomen, upper arm, or thigh via subcutaneous injection.
What Side Effects May Occur During Trulicity Treatment?
Like all medical interventions and medications, Trulicity may cause side effects that require careful monitoring because of its broad physiological effects. Medical authorities recommend exercising particular caution in individuals with certain genetic predispositions. Due to thyroid findings observed in laboratory studies, the medication is generally not recommended for individuals with a personal or family history of medullary thyroid carcinoma or similar thyroid disorders.
Patients should remain alert for signs suggesting thyroid-related complications, including:
- Swelling in the neck
- Difficulty swallowing
- Shortness of breath
- Hoarseness
Because the medication directly affects the digestive system by slowing gastric emptying, gastrointestinal complaints are common, particularly during the early stages of treatment. During the first weeks, while the stomach adapts to its altered function, patients may experience temporary reductions in daily comfort.
The most frequently reported gastrointestinal side effects include:
- Nausea
- Vomiting
- Diarrhea
- Loss of appetite
- Indigestion
These symptoms usually improve over time. However, severe nausea and vomiting may cause significant fluid loss. Since dehydration can impair kidney function, individuals using Trulicity should pay particular attention to maintaining adequate hydration throughout the day. Additionally, patients with a previous history of pancreatitis are generally not considered suitable candidates for this treatment. Persistent, severe abdominal pain radiating toward the back during therapy may indicate pancreatic inflammation and should prompt immediate medical evaluation.
Special attention is also required when Trulicity is used alongside other medications. Because gastric emptying is delayed, the absorption of oral medications may be altered. Patients taking medications with highly precise dosing requirements, such as thyroid hormone replacement therapy, may require adjustments to their dosing schedules. Individuals receiving insulin therapy may also require careful dose modifications to minimize the risk of hypoglycemia.
What Is the Cost of Trulicity in Türkiye and How Does SGK Reimbursement Work?
The long-term sustainability of any treatment is as important as its medical effectiveness. In Türkiye, the availability and pharmacy pricing of Trulicity represent major considerations for patients beginning treatment. The medication is available only by prescription through pharmacies and must be transported and stored according to strict cold-chain requirements. According to current data, a one-month supply consisting of four injection pens carries a relatively high retail cost. As of April 2026, the retail pharmacy price is approximately 13,238.20 TRY.
An examination of the Social Security Institution’s (SGK) reimbursement policies shows that the medication is not universally covered. Under the Health Implementation Communiqué (SUT), reimbursement is restricted by strict medical criteria. Merely having Type 2 diabetes is insufficient. Patients must also demonstrate inadequate glycemic control despite standard diabetes treatments and obtain a formal medical board report approved by three specialist physicians.
The medication’s increasing popularity for weight loss introduces a different reimbursement scenario. When prescribed solely for obesity or weight reduction in individuals without diabetes, its use is considered off-label. Under these circumstances, SGK provides no reimbursement whatsoever. Individuals pursuing weight-loss treatment must personally cover monthly expenses that can amount to tens of thousands of Turkish lira. Considering that obesity treatment typically extends over months or years, these cumulative medication costs become substantial. Many patients discontinue therapy because of financial limitations, frequently resulting in rapid weight regain.
What Are the Differences Between Trulicity and Ozempic?
As GLP-1 receptor agonists have become increasingly common in the treatment of metabolic diseases, patients have naturally begun comparing the available options. One of the best-known alternatives is Ozempic, whose active ingredient is semaglutide. Although both medications belong to the same therapeutic class, they differ in molecular design and biological potency. Numerous large-scale clinical trials have directly compared their effectiveness.
The primary areas in which the two medications differ include:
- Amount of weight loss
- Reduction in blood glucose levels
- Severity of nausea
- Injection pen design
Comparative studies have demonstrated that Ozempic generally produces greater reductions in HbA1c levels and more substantial weight loss than Trulicity. Patients receiving Ozempic more frequently achieve recommended glycemic targets, and greater reductions in body weight have been consistently observed compared with patients receiving Trulicity.
However, greater efficacy does not necessarily translate into a better overall patient experience. Due to its stronger biological effects, Ozempic is more frequently associated with nausea, vomiting, and gastrointestinal discomfort. Trulicity, in contrast, generally demonstrates a milder gastrointestinal side-effect profile and may therefore be easier for many patients to tolerate.
Another important distinction involves ease of administration. Trulicity features a fully automated, single-use injection pen with a concealed needle that automatically delivers the medication when pressed against the skin, making it particularly attractive for individuals with needle anxiety. Ozempic, by comparison, is supplied as a multidose pen that requires patients to attach a new needle before each use and manually select the appropriate dose. Consequently, physicians consider not only expected weight loss but also patient comfort and tolerance when selecting the most appropriate treatment.
Is It Possible to Overcome Obesity by Using Only Trulicity?
The feeling of fullness produced by Trulicity and similar injectable medications has led many individuals to believe that obesity can now be managed simply by taking medication. However, obesity is not merely a matter of poor willpower, laziness, or excessive eating. It is a complex systemic disease involving disrupted regulation of fat storage and energy expenditure influenced by genetic, environmental, and cellular factors. The body tends to recognize its highest achieved weight as its new physiological “normal” and naturally resists attempts to lose weight through either medication or dietary interventions.
Studies evaluating weight-loss outcomes with these medications generally show encouraging reductions during the first six months of treatment. Nevertheless, even when therapy continues unchanged, many patients experience a plateau after approximately eighteen months as the body gradually adapts. Metabolism slows, energy expenditure decreases, and further weight loss becomes increasingly difficult.
More importantly, the effects of these medications resemble wearing corrective glasses—you see clearly while wearing them, but the underlying vision problem returns once they are removed. When Trulicity or similar medications are discontinued due to cost, side effects, or other reasons, appetite suppression disappears and hunger often returns even more intensely than before treatment. Scientific evidence indicates that most patients regain a significant proportion of lost weight within the first year after discontinuing therapy, with additional weight regain occurring thereafter. This occurs because the medication temporarily mimics hormonal signaling without permanently altering digestive anatomy, potentially resulting in long-term financial burden and dependence on chronic pharmacological therapy.
Why Is Gastric Botox Considered a More Reliable Alternative Than Medications Such as Trulicity?
Considering the temporary benefits and systemic effects associated with medication therapy, localized endoscopic procedures such as gastric Botox offer a more comfortable and sustainable approach for weight management. Rather than relying on systemically circulating chemicals that affect multiple organs, gastric Botox directly slows the contractions of the stomach muscles, allowing patients to comfortably consume smaller meal portions without surgical incisions.
Whereas medication therapy may eventually plateau or result in rapid weight regain following discontinuation, gastric Botox may facilitate sustained portion control habits that contribute to meaningful long-term weight reduction. Instead of continuously delivering chemical appetite-suppressing signals throughout the body, gastric Botox locally targets the stomach muscles through a minimally invasive approach.
Today, gastric Botox is among the most commonly selected non-surgical weight management procedures. During this treatment, botulinum toxin is injected endoscopically into selected regions of the stomach without altering its anatomical structure. The procedure slows gastric emptying, allowing food to remain in the stomach longer. Localized injections into the upper portions of the stomach reduce appetite by influencing hunger-related physiological pathways. Patients awaken without organ removal or surgical alteration of the stomach but experience a significant reduction in appetite. Rather than suppressing hunger through systemic neurological pathways as medications do, gastric Botox naturally prolongs satiety by physically delaying gastric emptying.
Unlike surgical procedures that permanently alter anatomy, gastric Botox preserves the natural structure of the digestive system. Patients avoid surgical complications and lifelong nutritional deficiencies while extending satiety to support improvements in obesity-related conditions such as diabetes and hypertension through weight reduction.
From an economic perspective, gastric Botox may also represent a more practical long-term option. Whereas medications such as Trulicity require continuous monthly expenditures, gastric Botox is generally performed as a single short-term procedure. Performed endoscopically under sedation, patients typically resume normal daily activities within 15 to 20 minutes on the same day. Compared with years of medication costs and repetitive dieting attempts that often produce disappointing long-term outcomes, gastric Botox may offer meaningful advantages in terms of time, health, and overall cost.
How Can Trulicity Therapy Be Used During the Gastric Botox Process?
Advances in medical science have shown that different treatment modalities should not always be viewed as competitors but instead combined when appropriate to maximize patient benefit. In obesity treatment clinics, medications such as Trulicity, Ozempic, and similar agents are not categorically rejected. Instead, they are strategically incorporated during selected phases of the gastric Botox journey as supportive therapeutic tools. Gastric Botox and modern pharmacological treatments can complement one another effectively.
Potential advantages of combining medication with gastric Botox include:
- Accelerating weight loss in individuals with severe treatment-resistant obesity
- Supporting satiety signaling during the adaptation to smaller meal portions
- Helping control episodes of emotional eating
- Overcoming weight-loss plateaus
Patients with very high body weight and significant difficulty adhering to dietary recommendations may struggle during the initial stages of gastric Botox therapy or at various points throughout treatment. In these situations, physicians may prescribe short-term GLP-1 receptor agonist therapy alongside gastric Botox. During this limited period, patients benefit from both the localized satiety created by delayed gastric emptying and the centrally mediated appetite suppression provided by the medication, allowing treatment to proceed more comfortably. In this setting, the medication functions as a temporary supportive bridge that enhances the effectiveness of gastric Botox.
These medications may also play an important role later in the treatment course. Months after gastric Botox, weight loss may plateau because of metabolic adaptation, or patients may regain a modest amount of weight due to lifestyle changes. Whereas such situations previously led many individuals toward more invasive bariatric procedures, modern treatment strategies may instead involve a short course of appetite-suppressing medications such as Trulicity. When combined with a stomach already functioning more slowly because of gastric Botox, the medication’s appetite-suppressing effects on the brain can help patients resume healthy weight loss without exposure to the risks associated with major surgery.
Op. Dr. Ahmet Bekin was born in Istanbul in 1983. He graduated from the Faculty of Medicine at Kocaeli University in 2006 and completed his specialty training in the Department of General Surgery at Istanbul University Çapa Faculty of Medicine in 2011. After his specialization, he worked in the fields of hernia surgery, reflux surgery, obesity surgery, advanced laparoscopic surgery, and robotic surgery. In addition, he received training in endocrine surgery, oncological surgery, and minimally invasive surgery. He is currently accepting patients from Turkey as well as from countries such as Germany and France at his private clinic located in Istanbul.